At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- MZE829 (drug)
- How long the study runs
- Study runs about 19 months (dates as stated)
- About the drug or intervention
- MZE829 — drug: Capsules for oral administration
- Patient visit burden
- Not specified by the sponsor
In plain English
This Phase 2 study is testing a medicine called MZE829 in adults with a kidney disease linked to APOL1 gene changes (APOL1 high-risk genotype). The condition being studied is proteinuric kidney disease, which means the kidneys leak protein into the urine. The study is sponsored by Maze Therapeutics.
Who can take part
- Adults with an APOL1 high-risk gene pattern (G1/G1, G2/G2, or G1/G2)
- Long-term (chronic) kidney disease with ongoing protein in the urine (albuminuria)
- Other inclusion rules in the study plan also apply
Who may not be able to
- People who have had an organ or bone marrow transplant
- Cancer within the past 2 years, except some treated skin, cervical (stage 0) or prostate (stage 1) cancers
- Conditions that may change how the body absorbs medicine, such as previous weight-loss (bariatric) surgery
- Type 1 diabetes
- People who are pregnant or breastfeeding
- Other exclusion rules in the study plan also apply
What taking part involves
- • Taking the study medicine MZE829 — details of how it is given or how often are not stated — ask the trial team
Time commitment: Not stated — ask the trial team about how many visits are needed, how long the study lasts, and what taking part involves.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Testing a treatment
- Ages
- 18 Years to 68 Years
- Who
- All
- Number of participants
- 74
- Started
- 2025-02-05
- Last checked
- 2026-07
Plain English Summary
What is this study?
- • Testing a new treatment for proteinuric kidney disease
- • Phase2 - 74 participants
- • The purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease
Who can take part?
- • Ages 18 Years to 68 Years
- • Diagnosed with proteinuric kidney disease
Where?
- • Leicester - Research Site
- • London - Research Site
- • London - Research Site
- • London - Research Site
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease.
More detail
An open-label Phase 2 study is designed to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 68 Years
- Who can join: All genders
What the study is looking for
- ✓APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2
- ✓Chronic kidney disease with persistent albuminuria
Who cannot take part
- ✗Organ or bone marrow transplantation
- ✗History of active cancer within past 2 years, except for treated non-melanoma skin cancer, stage 0 cervical cancer,...
- ✗Conditions that may alter drug absorption, e.g., history of bariatric surgery
- ✗Type I diabetes
- ✗Pregnant or currently nursing
See the full criteria
Where Is This Study? (4 UK sites)
Research Site
Leicester LE5 4PW, United Kingdom
Research Site
London NW3 2QG, United Kingdom
Research Site
London SE19RT, United Kingdom
Research Site
London SE59RS, United Kingdom
How to Get in Touch
Maze Therapeutics
Sponsor contactCONTACT